Loading...
Natalizumab is a potent therapy for relapsing-remitting multiple sclerosis (MS), but its effects on immune surveillance in the central nervous system can come at a steep price — a risk for progressive multifocal leukoencephalopathy (PML), an opportunistic brain infection caused by the JC virus. A new study, sponsored and conducted by the manufacturer of natalizumab, provides important updates about PML risk with this monoclonal antibody therapy in MS and a practical approach for risk stratification.
To incorporate anti–JC virus antibody test results into a practical algorithm for estimating PML incidence, the investigators examined clinical trial and postmarketing registry data of MS patients treated with natalizumab and followed for up to 4…